Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) shares saw strong trading volume on Wednesday . 4,956,005 shares changed hands during trading, a decline of 13% from the previous session's volume of 5,728,009 shares.The stock last traded at $11.22 and had previously closed at $10.86.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Roivant Sciences in a research report on Thursday. They set a "buy" rating and a $19.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Wednesday, June 18th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $17.88.
View Our Latest Research Report on ROIV
Roivant Sciences Stock Up 3.1%
The business's 50 day moving average is $11.12 and its two-hundred day moving average is $10.87. The firm has a market capitalization of $7.87 billion, a P/E ratio of -46.28 and a beta of 1.15.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Thursday, May 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.15). The firm had revenue of $7.57 million for the quarter, compared to analyst estimates of $62.17 million. Roivant Sciences had a negative return on equity of 14.76% and a negative net margin of 225.71%. During the same period in the previous year, the firm earned ($0.23) earnings per share. As a group, equities analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.
Insider Activity
In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 577,007 shares of Roivant Sciences stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $11.46, for a total value of $6,612,500.22. Following the transaction, the insider directly owned 37,284,108 shares of the company's stock, valued at $427,275,877.68. The trade was a 1.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Eric Venker sold 566,278 shares of Roivant Sciences stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $11.22, for a total value of $6,353,639.16. Following the completion of the transaction, the chief operating officer directly owned 1,462,223 shares in the company, valued at approximately $16,406,142.06. This represents a 27.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 3,464,462 shares of company stock worth $39,098,856. Company insiders own 7.90% of the company's stock.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of ROIV. GAMMA Investing LLC grew its position in Roivant Sciences by 83.0% in the first quarter. GAMMA Investing LLC now owns 6,493 shares of the company's stock valued at $66,000 after acquiring an additional 2,945 shares during the period. Thompson Siegel & Walmsley LLC grew its holdings in shares of Roivant Sciences by 10.1% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 565,337 shares of the company's stock worth $6,688,000 after purchasing an additional 51,705 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Roivant Sciences by 478.6% during the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after purchasing an additional 1,948 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Roivant Sciences during the fourth quarter worth $995,000. Finally, Monimus Capital Management LP bought a new stake in shares of Roivant Sciences during the fourth quarter worth $1,621,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.